Education
About Us
Working with TipRanks
Follow Us
Bioline RX Ltd Sponsored ADR (BLRX)
NASDAQ:BLRX
BLRX Stock Chart & Stats
$3.00
-$0.02(-10.62%)
At close: 4:00 PM EST
$3.00
-$0.02(-10.62%)
Day’s Range― - ―
52-Week Range$2.30 - $14.71
Previous CloseN/A
Volume8.80M
Average Volume (3M)23.61K
Market Cap
$13.11M
Enterprise ValueN/A
Total Cash (Recent Filing)$28.16M
Total Debt (Recent Filing)$12.60M
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Mar 12, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding4,351,358
10 Day Avg. Volume24,146
30 Day Avg. Volume23,614
Financial Highlights & Ratios
PEG Ratio0.84
Price to Book (P/B)50.79
Price to Sales (P/S)23.63
P/FCF Ratio-15.56
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$12.00Price Target Upside300.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsMotixafortide demonstrated the ability to mobilize a high yield of CD34 cells, surpassing existing FDA-approved treatments.
Joint VentureBioLineRx announced a Joint Venture with Hemispherian AS for the development of GLIX1, a small molecule in development for the treatment of glioblastoma and other cancers.
Orphan Drug DesignationGLIX1 has been granted Orphan Drug Designation by both the FDA.
Bears Say
Bioline RX Ltd Sponsored ADR News
BLRX FAQ
What was Bioline RX Ltd Sponsored ADR’s price range in the past 12 months?
Bioline RX Ltd Sponsored ADR lowest stock price was $2.30 and its highest was $14.71 in the past 12 months.
What is Bioline RX Ltd Sponsored ADR’s market cap?
Bioline RX Ltd Sponsored ADR’s market cap is $13.11M.
When is Bioline RX Ltd Sponsored ADR’s upcoming earnings report date?
Bioline RX Ltd Sponsored ADR’s upcoming earnings report date is Mar 12, 2026 which is in 77 days.
How were Bioline RX Ltd Sponsored ADR’s earnings last quarter?
Bioline RX Ltd Sponsored ADR released its earnings results on Nov 24, 2025. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.67 by $0.67.
Is Bioline RX Ltd Sponsored ADR overvalued?
According to Wall Street analysts Bioline RX Ltd Sponsored ADR’s price is currently Undervalued.
Does Bioline RX Ltd Sponsored ADR pay dividends?
Bioline RX Ltd Sponsored ADR does not currently pay dividends.
What is Bioline RX Ltd Sponsored ADR’s EPS estimate?
Bioline RX Ltd Sponsored ADR’s EPS estimate is -0.39.
How many shares outstanding does Bioline RX Ltd Sponsored ADR have?
Bioline RX Ltd Sponsored ADR has 4,351,358 shares outstanding.
What happened to Bioline RX Ltd Sponsored ADR’s price movement after its last earnings report?
Bioline RX Ltd Sponsored ADR reported an EPS of $0 in its last earnings report, beating expectations of -$0.67. Following the earnings report the stock price went up 7.692%.
Which hedge fund is a major shareholder of Bioline RX Ltd Sponsored ADR?
Currently, no hedge funds are holding shares in BLRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bioline RX Ltd Sponsored ADR
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
BLRX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive developments in R&D ventures and strong financial management, offset by minimal revenue growth and reduced operational expenses. The company's strategic focus on innovative treatments and a solid cash position are promising, but current revenue generation and market penetration remain challenges.View all BLRX earnings summariesBLRX Stock 12 Month Forecast
Average Price Target
$12.00
▲(300.00% Upside)
Technical Analysis
Synlogic
―
Moleculin Biotech
―
Citius Pharmaceuticals
―
Chemomab Therapeutics
―
Passage Bio
―
Ownership Overview
―
Insiders
<0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors